Estimating The Cost Of Delayed Generic Drug Entry To Medicaid

Delays in market entry of generic drugs are common. This study sought to identify the prevalence of delayed entry, the reasons for the delays, and the delays’ effects on Medicaid spending in a recent cohort of brand-name medications. We estimated excess Medicaid spending in 2010–16 in the delayed quarter-years after accounting for market average predictions of brand-name market share, ratios of generic to brand-name prices, and Medicaid rebates...